News
Press Center
Norilsk Nickel plans to invest more than $12bn in production development over the next five years in order to boost production volumes, Mr. Potanin told President Vladimir Putin in a meeting on December 10th. More
Topics Norilsk Nickel
03.12.2018
The first place in the nomination «Medicine of choice for the treatment and prevention of SARS and influenza among children» was granted to «Polyoxidonium», produced by NGO Petrovax Pharm.
More
Topics Petrovax Pharm 
20.11.2018
The company aims to benefit from an expected demand rise on the part of electric vehicle manufacturers.
More
Topics Norilsk Nickel 03.10.2018
Expert, a magazine, recently published its annual ranking of Russia’s largest exporters for 2017, listing Norilsk Nickel as number five. The commentary on the ranking notes that in 2017 the company’s [export] growth increased more than twofold, bringing it to up four places to number five.
More
Topics Norilsk Nickel 
06.08.2018
In July 2018, Petrovax Pharm received Marketing Authorization No. LP-004951 for Grippol® Quadrivalent, a 4-valent inactivated subunit adjuvanted vaccine designed for prevention of influenza. It is the most advanced flu vaccine in the world that employs an antigen sparing technology and has a high preventive activity and safety.
More
Topics Petrovax Pharm